3P Biopharmaceuticals_Betalutin

3P Biopharmaceuticals and Nordic Nanovector have extended partnership for Betalutin® late stage manufacturing for B-cell non-Hodgkin lymphoma (NHL) treatment

Wednesday June 26th, 2019 | General

3P Biopharmaceuticals (3P) and Norwegian biopharmaceutical company Nordic Nanovector have extended their collaboration agreement for the biopharmaceutical development of Betalutin® late stage manufacturing for B-cell non-Hodgkin lymphoma (NHL) treatment. The non-Hodgkin lymphoma (NHL) is cancer that starts in white blood cells called lymphocytes, which are part of the body’s immune system. 3P and Nordic Nanovector started their […]

3P Biopharmaceuticals enters into manufacturing agreement with the Swedish company Affibody

Thursday June 6th, 2019 | General

The arrangement covers process transfer, process development and GMP manufacture of Affibody’s candidate 3P Biopharmaceuticals, a leading CDMO specialized in the process development and GMP manufacturing of biologics, has signed a collaboration agreement with the Swedish company Affibody for the process transfer, scale-up and GMP commercial manufacturing of a recombinant protein sole property of Affibody. […]

Large-scale manufacturing process for Strangvac now secured

Tuesday April 2nd, 2019 | General

We are so glad to be part of such an exciting project with the Swedish company INTERVACC, who we are working with on manufacturing of Strangvac® including the large-scale production of the vaccine against equine strangles. The biotechnology company Intervacc has together with 3P Biopharmaceuticals, the contracted manufacturer of Strangvac, secured large-scale production of the […]

3P Biopharmaceuticals enters into a new manufacturing agreement with the Dutch Biotech Company Xenikos

Monday March 11th, 2019 | General

Pamplona, 11th of March, 2019. 3P Biopharmaceuticals, a leading CDMO specialized in the process development and GMP manufacturing of biologics, has signed a collaboration agreement with the Dutch biotech company Xenikos B. V. (Xenikos) that will cover the global manufacturing of Xenikos’ proprietary lead product candidate T-Guard®. 3P and Xenikos started their collaboration in 2015 […]

Expansion of analytical capacities by 3P Biopharmaceuticals

Wednesday February 27th, 2019 | General

3P Biopharmaceuticals has recently increased its analytical capacities and capabilities.   The 3P Analytical Development Area is one of the company’s core competences and is crucial to the state-of-the-art technologies as well as services it provides to the clients.   The development of analytical methods is an essential activity in any process development and manufacturing […]